ClinicalTrials.gg
CompletedNCT03921775Updated May 15, 2020

A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery

A Phase 3 interventional study of Remimazolam Tosilate and Propofol in Anesthesia for Elective Surgery Patients, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-05-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy and safety of remimazolam tosilate compared to propofol for general anesthesia during elective surgery.

02

Conditions studied

  • Anesthesia for Elective Surgery Patients
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclution Criteria:

  1. 18\~60 years, female or male
  2. Patients scheduled for an elective surgical procedure(mechanical ventilation via endotracheal tube)
  3. : 18\~30 kg/m2
  4. Patients understand clearly and participate in the study voluntarily, and sign the

Exclusion criteria:

  1. Patients scheduled for emergency surgery
  2. Patients with a history of drug abuse and / or alcohol abuse 2 years prior to the screening period
  3. One or more of the laboratory findings fall out of the limitations for this study(,,,etc.)
  4. Pregnant women or those in lactation period
  5. Allergic to drugs used in the study
  6. Patients with respiratory management difficulties (Modified Mallampati grade IV)
  7. Patients have participated in other clinical trial within the 3 months prior to randomization
  8. Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be inappropriate for the subject for any other reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Treatment group A

    IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance

    Drug: Remimazolam Tosilate

  • Active comparator
    Treatment B

    IV pumping of propofol at 120\~150mg/kg/h for anesthesia induction and 3\~12mg/kg/h for anesthesia maintenance

    Drug: Propofol

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage(%) of paticipants who experienced successful anesthesia during operation in each group

    Time frame: Average of 2 hours

Secondary outcomes

  1. Time from start of investigational medicinal product administration to loss of consciousness

    Time frame: Average of 2 hours

  2. Time from stop of investigational medicinal product to MOAA/S Score=5

    Time frame: Average of 2 hours

  3. Time from stop of investigational medicinal product to Aldrete Score>9

    Time frame: Average of 2 hours

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 010, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Dec 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2019
First posted
Apr 19, 2019
StartActual
May 13, 2019
Primary completionActual
Dec 30, 2019
CompletionActual
Dec 30, 2019
Last update
May 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03921775
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
May 13, 2019
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Last update
May 15, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion